🔎 Trials Near Me

Home › Ewing Sarcoma › Massachusetts › Boston

Ewing Sarcoma clinical trials in Boston, MA

6 studies for Ewing Sarcoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

RecruitingPhase 1
  • Dana Farber Cancer Institute, Boston
Ages 2 and older · All sexes · Updated Sep 25, 2026 · NCT07297979

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute ( Site 1013), Boston
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103

Lurbinectedin in FET-Fused Tumors

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
Ages 10 and older · All sexes · Updated Sep 2, 2026 · NCT05918640

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

RecruitingPhase 1
  • Mass General Brigham Cancer Institute, Boston
  • Dana Farber Cancer Institute, Boston
Ages 16 and older · All sexes · Updated Jun 2, 2026 · NCT07197554

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

RecruitingPhase 1/2
  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Ages 12 to 49 · All sexes · Updated Feb 19, 2026 · NCT06709495

Ewing Sarcoma trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.